- ISIN
- US09077B1044
- CUSIP
- 09077B104
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 16, 2020
Highlights
- EPS (TTM)
- -$1.10
- Gross Profit (TTM)
- -$12.46M
- EBITDA (TTM)
- -$67.70M
- Year Range
- $3.12 - $71.50
- Target Price
- $5.00
- ROA (TTM)
- -467.94%
- ROE (TTM)
- 178.80%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BCAB Performance Chart
BioAtla, Inc. (BCAB) is down 87.3% since the beginning of the year. At $4 per share, BCAB is trading 94.9% below its 52-week high of $72. Investors who bought $1,000 worth of BCAB shares 5 years ago would now be looking at an investment worth $2.
Loading charts...
Returns By Period
BioAtla, Inc. (BCAB) has returned -87.25% so far this year and -81.96% over the past 12 months.
BioAtla, Inc.
- 1D
- -0.96%
- 1M
- -1.90%
- YTD
- -87.25%
- 6M
- -90.93%
- 1Y
- -81.96%
- 3Y*
- -72.55%
- 5Y*
- -71.61%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
BCAB Monthly Returns History
Based on dividend-adjusted daily data since Dec 16, 2020, BCAB's average daily return is -0.18%, while the average monthly return is -3.75%.
Historically, 31% of months were positive and 69% were negative. The best month was Aug 2022 with a return of +156.2%, while the worst month was Dec 2024 at -64.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 9 months.
On a daily basis, BCAB closed higher 44% of trading days. The best single day was Aug 10, 2022 with a return of +83.1%, while the worst single day was Jan 10, 2023 at -46.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -52.62% | -8.03% | -34.92% | -47.70% | -6.65% | -7.89% | -87.25% | ||||||
| 2025 | -20.50% | -30.68% | 6.45% | 40.20% | -15.88% | -3.18% | -9.32% | 26.84% | 51.02% | 1.67% | 29.25% | -37.20% | -3.97% |
| 2024 | -22.15% | 40.99% | 27.41% | -34.45% | -33.04% | -9.27% | 32.12% | -2.21% | -0.56% | 9.09% | -12.50% | -64.81% | -75.97% |
| 2023 | -54.06% | -21.37% | -10.07% | 25.75% | -6.53% | -4.76% | -0.33% | -16.05% | -32.27% | -13.53% | 20.41% | 38.98% | -70.18% |
| 2022 | -51.30% | -32.22% | -22.84% | -30.40% | -30.75% | 18.26% | 19.30% | 156.18% | -11.60% | -10.52% | 59.80% | -25.07% | -57.97% |
| 2021 | 29.29% | 20.76% | -4.26% | -2.46% | -13.19% | -1.56% | -3.28% | 0.24% | -28.35% | -0.71% | -13.62% | -22.26% | -42.28% |
Benchmark Metrics
BioAtla, Inc. has an annualized alpha of -49.81%, beta of 1.67, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since December 16, 2020.
- This stock participated in 247.43% of S&P 500 Index downside but only -67.26% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -49.81%
- Beta
- 1.67
- R²
- 0.06
- Upside Capture
- -67.26%
- Downside Capture
- 247.43%
Return for Risk
Risk / Return Rank
BCAB ranks 13 for risk / return — in the bottom 13% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BioAtla, Inc. (BCAB) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BCAB | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.65 | ||
| Sortino ratioReturn per unit of downside risk | -3.59 | ||
| Omega ratioGain probability vs. loss probability | 0.90 | 1.37 | -0.47 |
| Calmar ratioReturn relative to maximum drawdown | -0.87 | 2.78 | -3.65 |
| Martin ratioReturn relative to average drawdown | -1.33 | 12.44 | -13.77 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the BioAtla, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BioAtla, Inc. was 99.91%, occurring on Jun 8, 2026. The portfolio has not yet recovered.
The current BioAtla, Inc. drawdown is 99.90%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.91%Jun 2026 | 5y 2mo | — | 5y 3moMar 2021 - now |
2021 correction2021 | -13.65%Mar 2021 | 14d | 4d | 18dFeb 2021 - Mar 2021 |
2020 pullback2020 | -9.50%Dec 2020 | 6d | 13d | 19dDec 2020 - Jan 2021 |
2021 pullback2021 | -7.86%Jan 2021 | 2d | 7d | 9dJan 2021 - Feb 2021 |
2021 pullback2021 | -7.65%Jan 2021 | 4d | 6d | 10dJan 2021 - Jan 2021 |
Drawdown Indicators
| BCAB | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.91% | -56.78% | -43.13% |
Max Drawdown (1Y)Largest decline over 1 year | -94.57% | -9.10% | -85.47% |
Max Drawdown (3Y)Largest decline over 3 years | -98.31% | -18.90% | -79.41% |
Max Drawdown (5Y)Largest decline over 5 years | -99.85% | -25.43% | -74.42% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.90% | -1.80% | -98.10% |
Average DrawdownAverage peak-to-trough decline | -84.84% | -10.71% | -74.13% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 61.49% | 2.03% | +59.46% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BioAtla, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BioAtla, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BCAB
Add BioAtla, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BCAB